Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZILIENT4: Zipalertinib vs Placebo in Early Stage NSCLC with Uncommon EGFR Mutations
NCT07128199Phase 3Recruiting
- Sponsor
- Taiho Oncology
- Start
- Dec 2025
- Primary completion
- Oct 2029
- Modality
- Small Molecules
- Countries
- 24
01
Overview
A Phase 3 trial of zipalertinib in non-small cell lung cancer (NSCLC), sponsored by Taiho Oncology. Started Dec 2025; status: recruiting.
02
Drugs
zipalertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07128199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128199.